A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases.

Kumutnart Chanprapaph Chutima Seree-Aphinan Ploysyne RattanakaemakornCherrin PomsoongYanisa RatanapokasatitChavachol SetthaudomArunee ThitithanyanontAphinyaphiwat SuriyoThanitta SuangtamaiPoonkiat Suchonwanitnull null

Published in: The British journal of dermatology (2023)

Among participants with IMDDs, ChAdOx1-S[recombinant] showed good immunogenicity among patients with psoriasis, but demonstrated lower levels of immunogenicity for patients with AIBD. Some patients, especially patients with AIBD, should be closely monitored as they may require treatment escalation within 1 month postvaccination.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
cell free
open label
randomized controlled trial
patient reported outcomes